CN1222350A - Medicine composition for odinopoenia of long pregnancy - Google Patents
Medicine composition for odinopoenia of long pregnancy Download PDFInfo
- Publication number
- CN1222350A CN1222350A CN 98100308 CN98100308A CN1222350A CN 1222350 A CN1222350 A CN 1222350A CN 98100308 CN98100308 CN 98100308 CN 98100308 A CN98100308 A CN 98100308A CN 1222350 A CN1222350 A CN 1222350A
- Authority
- CN
- China
- Prior art keywords
- gestation
- prostaglandin
- ethacridine
- combination drug
- odinopoenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine composition contains rivanol, anti-progestational hormone and prostaglandin, and the anti-progestational hormone has strong congeniality to progestational hormone acceptor, support effect to foetal membrane and inhibitory action to the decomposition of hysteromyo- and cervical collagen. It can shorten odinopoenia period to 3-4 hr, relief the patient's pain and reduce the labor strength of the medical and nursing staff.
Description
The present invention relates to a kind of medical complex that is used for the induction of labour, it is specially adapted to (more than three months) induced labor of big month.
The medicine of the induction of labour at present is a lot, as: R2323 (18-methylnorgestrienon), PG05 (15-methyl PGF25), Ru486 (mifepristone) etc., its shortcoming is: induced labor rate not high (about 80%), the induced labor time is long, use inconvenience, hemorrhage many, can only be used for early pregnancy.And list is used ethacridine, and for the solar month of 30 days induced labor, the induced labor rate is higher; But for (more than three months) induced labor of big month, list is used ethacridine, and not only induced labor rate is a problem, and the induced labor time is long, and is hemorrhage many, and pain is strong, and the misery that causes to the puerpera is very big; In addition, because the induced labor time is long, the puerpera need be in hospital, and then medical personnel are on duty night, add the groan of puerpera's misery, make that medical personnel's body and mind is extremely tired.
The object of the present invention is to provide a kind of combination drug, it can shorten the induced labor time, alleviates puerpera's pain, and reduces medical personnel's labor intensity.
Combination drug of the present invention is, in an administration unit, compound ethacridine, gestation and the prostaglandin of containing, wherein gestation possesses with progesterone receptor stronger affinity is arranged, it has the support effect to after birth, and uterus muscle and Cervical collagen decomposition are had inhibitory action.
Pharmacology analysis: the process of the induction of labour is actually the process of termination of pregnancy artificially.The condition of finishing this process is that effective uterine contraction appears in cervical maturing then, finishes childbirth.Ethacridine can sterilize, and stimulates uterine contraction, and uterus muscle contraction frequency and amplitude are improved, and simultaneously, ethacridine can make cervical maturing, and the high resilience that becomes; Gestation and progesterone receptor have stronger affinity, and it makes the uterus muscle excitement, and cervix uteri collagen decomposition power is descended, and therefore, with ethacridine and gestation and usefulness, can make the decidual cell necrosis, and discharge the endogenous prostaglandin.Prostaglandin can make uterine contraction, cervix maturation, and luteolysis suppresses effects such as neural excitation.So add excited uterus type prostaglandin again, the inevitable sensitivity of uterus to prostaglandin that obviously improve promotes cervix maturation, lax, expansion simultaneously.Do not having under the situation of obvious pain, causing that the uterus shrinks strongly, causing miscarriage.
According to the present invention, the gestation in this combination drug, the following chemical compound of optional usefulness:
11 β-((4-N, N-dimethylamino)-phenyl)-17 β hydroxyl-17 α propinyls-4,9 (10)-female (steroid) diene-3-ketone (Ru486)
11 β-P-anisyl-17 beta-hydroxyl-17 alphas-acetenyl-4,9 (10)-female (steroid) diene-3-ketone
11 β-((4-dimethylamino) phenyl)-17 Alpha-hydroxy-17 β-(3-hydroxypropyl)-13 Alpha-Methyls-4,9 (10)-property diene-3-ketone
11 β-[4-(dimethylamino) phenyl]-17 beta-hydroxyl-17 alphas-female alkene of (1-propinyl)-4--3-ketone
11 β-female the alkene of (4-acetylphenyl)-17 beta-hydroxies-4--3-ketone
11 β-(4-acetylphenyl)-17 beta-hydroxyl-17 alphas-female alkene of (1-propinyl)-4--3-ketone
11 β-[4-(3-furyl) phenyl]-17 beta-hydroxyl-17 alphas-female alkene of (1-propinyl)-4--3-ketone
The chemical compound of more than enumerating not is all, and all have the gestation of affinity by force with progesterone receptor, same being suitable for.
According to the present invention, contained ethacridine in this combination drug, the ratio of gestation and prostaglandin is: 1: 1～10: 0.005～0.1, preferred plan is: 1: 2～6: 0.008～0.08.During use, can use separatedly, continuously or simultaneously.If necessary, can suitably add some blocker, so that delay the time that ethacridine, gestation or prostaglandin discharge.This combination drug can be made forms such as ball, capsule, tablet, carries out orally, and in the intestines and stomach or non-through the intestinal medication, mode of priority is the intestines and stomach innerlich anwenden.
To 500 many cases more than three months the anemia of pregnant woman adopt this combination drug, from the medication to the fetus, give birth to, the time is short, and is painful few, safe and reliable.To the primipara, average total stage of labor only needs four hours, and total effective rate is 98% (anemia of pregnant woman of residue 2%, because gestation reaches 7,8 months month, so total stage of labor was above four hours); To the multipara, to give birth to from the fetus of taking medicine, paroxysmal pain is not obvious, and average total stage of labor only is three hours, and total effective rate is 100%.
Embodiment 1:
1). ethacridine 100mg,
2). 11 β-((4-N, N-dimethylamino)-phenyl)-17 β hydroxyl-17 α propinyls-
4,9 (10)-female (steroid) diene-3-ketone (Ru486), 150mg,
3). rice rope 1mg,
With 1), 2) and 3) in the capsule that is placed in after mixing.Give the maternity dress usefulness in pregnant 13 weeks then,
The time that begins to take medicine is points in mornings 9,12 noon about 45, and fetus is given birth to, and is pregnant
It is painful that the woman does not feel basically.
Embodiment 2:
With the 100mg ethacridine, 200mg Ru486 and 1.2mg rice rope are coated on the polyoxyethylene/polyoxypropylene film (PLURONIO F68) after compound; Give the maternity dress usefulness in pregnant 26 weeks, 9 of mornings begin to take medicine, in afternoon about 1: 50, fetus is given birth to.The anemia of pregnant woman has pain, but not strong.
Claims (2)
1. a combination drug that is used for the big month induction of labour is characterized in that this combination drug is, in an administration unit, and compound ethacridine, gestation and the prostaglandin of containing, wherein gestation possesses with progesterone receptor stronger affinity is arranged.
2. the combination drug that is used for the big month induction of labour according to claim 1, it is characterized in that in this combination drug, contained ethacridine, the ratio of gestation and prostaglandin is: 1: 1～10: 0.005～0.1, preferred plan is: 1: 2～6: 0.008～0.08.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98100308 CN1085078C (en) | 1998-01-07 | 1998-01-07 | Medicine composition for odinopoenia of long pregnancy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98100308 CN1085078C (en) | 1998-01-07 | 1998-01-07 | Medicine composition for odinopoenia of long pregnancy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1222350A true CN1222350A (en) | 1999-07-14 |
| CN1085078C CN1085078C (en) | 2002-05-22 |
Family
ID=5215951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98100308 Expired - Fee Related CN1085078C (en) | 1998-01-07 | 1998-01-07 | Medicine composition for odinopoenia of long pregnancy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1085078C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112909A1 (en) * | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2018068021A1 (en) * | 2016-10-07 | 2018-04-12 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
-
1998
- 1998-01-07 CN CN 98100308 patent/CN1085078C/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| CN108713023A (en) * | 2015-12-23 | 2018-10-26 | 欧瑞克制药公司 | Glucocorticoid receptor inhibitor |
| US11208432B2 (en) | 2015-12-23 | 2021-12-28 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017112909A1 (en) * | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| CN108713023B (en) * | 2015-12-23 | 2021-10-26 | 欧瑞克制药公司 | Glucocorticoid receptor inhibitors |
| AU2016379417B2 (en) * | 2015-12-23 | 2020-09-24 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2018068021A1 (en) * | 2016-10-07 | 2018-04-12 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| AU2017339510B2 (en) * | 2016-10-07 | 2020-07-30 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US10723759B2 (en) | 2016-10-07 | 2020-07-28 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US10836789B2 (en) | 2016-10-07 | 2020-11-17 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US10472387B2 (en) | 2016-10-07 | 2019-11-12 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| AU2021202016B2 (en) * | 2016-10-07 | 2022-01-06 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| AU2021202016C1 (en) * | 2016-10-07 | 2022-06-09 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1085078C (en) | 2002-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Albright | The effect of hormones on osteogenesis in man | |
| US5968519A (en) | Method for the treatment of topical inflammatory diseases | |
| JPS61178917A (en) | Manufacture of composition comprising anti-estrogen and carrier | |
| JPH09502194A (en) | Alternative therapeutic formulation comprising at least one progestogen and at least one estrogen | |
| JPH1129481A (en) | Ultra low dosage contraceptive decreasing bleeding at menses and having sustained activity | |
| JP2000516576A (en) | Oral contraceptives as pharmaceuticals with estrogen-androgen-progestin combination | |
| EA031227B1 (en) | METHOD OF ORAL CONTRACEPTION IN WOMEN, METHOD FOR PREVENTING NON-DESIRABLE BLEEDING DURING ORAL CONTRACEPTION IN WOMEN AND PHARMACEUTICAL KIT FOR APPLICATION IN THESE METHODS | |
| MXPA04005445A (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology. | |
| Lauritzen | Clinical use of oestrogens and progestogens | |
| EP1100509A1 (en) | Use of biogenic estrogen sulfamates for hormone replacement therapy | |
| CN1085078C (en) | Medicine composition for odinopoenia of long pregnancy | |
| Ribot et al. | Preventive effects of transdermal administration of 17| 3-estradiol on postmenopausal bone loss: A 2-year prospective study | |
| DE69637313T2 (en) | USE OF NITROGENOXYDDENORS OR ANTAGONISTS FOR REGULATING THE EXPANSION OF ZERVIX | |
| CN1672685A (en) | New contraception medicine | |
| JP2003511399A (en) | Mesoprogestin (progesterone receptor modulator) as a component of female contraceptives | |
| KR100232833B1 (en) | Method of preventing or inhibiting fertilization | |
| Guillebaud | Contraception for the older woman | |
| Corner | Corpus Luteum Hormone | |
| Gruber et al. | Gender-specific medicine: the new profile of gynecology | |
| Amrutha | Comparative Study of Efficacy and Safety of Mifepristone and Foley’s Catheter in Induction of Labour | |
| Hall | Gonadotropic Hormone of Pregnant Mares' Serum: Its Clinical Use in Gynecology | |
| Allen | The chemical and physiological properties, and clinical uses of the corpus luteum hormone, progesterone | |
| Lu et al. | Effects of the antiestrogen anordiol on ovulation and endometrial histology in the rat | |
| Hamblen | The use of estrogens in obstetrics and gynecology | |
| Аттаева | REHABILITATION OF PATIENTS WITH EXTERNAL GENITAL ENDOMETRIOSIS AFTER SURGICAL TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Shen Zhihua Document name: payment instructions |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |